443 related articles for article (PubMed ID: 16371232)
1. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
[TBL] [Abstract][Full Text] [Related]
2. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
4. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
[TBL] [Abstract][Full Text] [Related]
5. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
[TBL] [Abstract][Full Text] [Related]
6. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain.
Broekman ML; Comer LA; Hyman BT; Sena-Esteves M
Neuroscience; 2006; 138(2):501-10. PubMed ID: 16414198
[TBL] [Abstract][Full Text] [Related]
7. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy strategies for hemophilia: benefits versus risks.
Petrus I; Chuah M; VandenDriessche T
J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
[TBL] [Abstract][Full Text] [Related]
9. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
Liu L; Mah C; Fletcher BS
Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for hemophilia.
Lynch CM
Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
[TBL] [Abstract][Full Text] [Related]
11. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
Ogata K; Mimuro J; Kikuchi J; Tabata T; Ueda Y; Naito M; Madoiwa S; Takano K; Hasegawa M; Ozawa K; Sakata Y
Gene Ther; 2004 Feb; 11(3):253-9. PubMed ID: 14737084
[TBL] [Abstract][Full Text] [Related]
12. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.
Sarkar R; Tetreault R; Gao G; Wang L; Bell P; Chandler R; Wilson JM; Kazazian HH
Blood; 2004 Feb; 103(4):1253-60. PubMed ID: 14551134
[TBL] [Abstract][Full Text] [Related]
13. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
[TBL] [Abstract][Full Text] [Related]
14. Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.
Couto LB
Semin Thromb Hemost; 2004 Apr; 30(2):161-71. PubMed ID: 15118928
[TBL] [Abstract][Full Text] [Related]
15. Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.
Zhu F; Liu Z; Miao J; Qu H; Chi X
Sci China Life Sci; 2012 Jun; 55(6):521-6. PubMed ID: 22744182
[TBL] [Abstract][Full Text] [Related]
16. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice.
Bristol JA; Shirley P; Idamakanti N; Kaleko M; Connelly S
Mol Ther; 2000 Sep; 2(3):223-32. PubMed ID: 10985953
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
[TBL] [Abstract][Full Text] [Related]
18. FVIII gene delivery by muscle electroporation corrects murine hemophilia A.
Long YC; Jaichandran S; Ho LP; Tien SL; Tan SY; Kon OL
J Gene Med; 2005 Apr; 7(4):494-505. PubMed ID: 15521095
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.
Connelly S; Andrews JL; Gallo-Penn AM; Tagliavacca L; Kaufman RJ; Kaleko M
Thromb Haemost; 1999 Feb; 81(2):234-9. PubMed ID: 10063998
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
